Novavax COVID-19 vaccine
Vaccine candidate against COVID-19
Novavax COVID-19 vaccine ▸ Facts ▸ Comments ▸ News ▸ Videos
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). Full results from Nuvaxovid's pivotal phase III trial were published in December 2021.
| 0 shares | ShareTweetSavePostSend |
You Might Like
SII gets govt nod to export 32.4 lakh doses of Covovax vaccine to USThe government has allowed Serum Institute of India (SII) to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported..IndiaTimes - Published | |
Covid-19 vaccine: SII's Covovax gets nod for emergency use in children aged 7 to 11 yearsThe DCGI had approved Covovax for restricted emergency use in adults on December 28, 2021, and in 12-17 years age group on March 9, 2022.DNA - Published Also reported by •IndiaTimes | |
Covovax vaccine: Government panel recommends emergency approval for use in 7-11 year oldsThe countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase.DNA - Published Also reported by •IndiaTimes | |
Covid-19 vaccine: SII significantly lowers price of each dose of CovovaxThis comes a day after Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres.DNA - Published | |
SII lowers each dose of Covovax jab from Rs 900 to Rs 225 excluding taxesIndiaTimes - Published | |
Covid-19 vaccine Covovax now available for children in India: Adar PoonawallaSerum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the Covid-19 vaccine Covovax is now available in India for children. He also hailed PM Narendra Modi for his vision of providing..IndiaTimes - Published | |
Govt unlikely to procure SII’s Covovax for 12-17 age groupAs majority of youngsters has already taken the first dose of Covid vaccine, the government is unlikely to procure Serum Institute of India’s Covovax for use in adolescents of 12-17 years under the..IndiaTimes - Published | |
SII gets NTAGI nod for use of Covovax in 12-17 age groupIndiaTimes - Published | |
NTAGI panel recommends inclusion of Covovax in inoculation drive for 12-17 age groupSerum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, rDNA - Published Also reported by •IndiaTimes | |
SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age groupCovovax is the 4th Covid vaccine authorised for administration in 12 years and above after ZyCoV-D, Bharat Biotech's Covaxin, Biological E's Corbevax.DNA - Published | |
SII’s Covovax for those aged 12+ gets panel nodThe Covid-19 working group under the government’s vaccine advisory body has recommended use of the Serum Institute of India’s Covovax in the national vaccination programme for those aged 12 years..IndiaTimes - Published | |
SII's Covovax recommended by government panel for inclusion in national Covid-19 vaccination driveIndia's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group.DNA - Published | |
NTAGI's Covid working group to review SII's Covovax data for use in 12 year olds and aboveIndiaTimes - Published | Novavax says its Covid vaccine gets India authorisation for adolescentsNovavax Inc on Tuesday said that the Drugs Controller General of India (DCGI) has granted emergency use authorisation for its Covid-19 vaccine for adolescents aged 12 to 17 in the country. The..IndiaTimes - Published |
Covid-19: Covovax gets DCGI’s EUA nod for 12-17-year-oldsIn a move that will further expand the basket of Covid vaccines approved for adolescents, the drug regulator has given emergency approval to Serum Institute of India’s Covovax for use in 12-17 year..IndiaTimes - Published | DCGI's EUA nod to Covovax for 12-17 years age groupIndia's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official..IndiaTimes - Published |
SII's Covovax granted emergency use approval for adults, children above 12The government has still not not taken a decision on vaccinating those aged below 15 years.DNA - Published | Covid-19: SII's Covovax vaccine recommended for Phase 3 trial as booster dose in adultsThe Pune-based SII had sought the permission from the DCGI to conduct Phase 3 study to evaluate the safety and immunogenicity of Covovax.DNA - Published Also reported by •IndiaTimes |
Government panel recommends EUA for Covid vaccine Covovax for 12-17 age groupPrakash Kumar Singh, director-government and regulatory affairs at Serum Institute of India (SII), had submitted an application to the DCGI on February 21, seeking EUA for Covovax for the 12 to 17..IndiaTimes - Published | SII seeks permission for phase-3 study of Covid vaccine Covovax as booster dose in adultsIndiaTimes - Published Also reported by •DNA |
230 kids aged 2-6 become youngest to get Covid jabs in Covovax trialA group of 230 children aged two to six have become the youngest in the country to get a Covid vaccine after they were given at least one dose during trials of the Covovax jab, manufacturer Serum..IndiaTimes - Published | India approves Corbevax, Covovax vaccines for emergency useIndiaTimes - Published |
Covovax approval to strengthen immunization efforts in India, lower & middle income countries: SIIIndiaTimes - Published | Bio E's Corbevax, SII's Covovax & antiviral drug Molnupiravir get EUA nodIn a significant boost for India’s fight against Covid-19, the Central Drugs Standard Control Organisation (CDSCO) has granted emergency use authorisation for two more Covid-19 vaccines – Corbevax..IndiaTimes - Published |
Covid-19: Govt approves emergency use of Corbevax and Covovax vaccines and anti-viral pill MolnupiravirThe government on Tuesday announced that it has approved emergency use of two more Covid-19 vaccines - Corbevax and Covovax - and Molnupiravir, an anti-viral pill. With the nod from the government for..IndiaTimes - Published | BREAKING: Corbevax, Covovax, anti-viral drug Molnupiravir approved for emergency use in IndiaThe vaccines that have so far received emergency use authorisation have increased to 8, as of now.DNA - Published |
Govt panel recommends EUA for Covid-19 vaccines Covovax, Corbevax, anti-Covid pill molnupiravirIndiaTimes - Published | CDSCO panel recommends emergency use authorisation for SII's Covid vaccine CovovaxIndiaTimes - Published |
Yechury questions Modi govt intent on not allowing CovovaxIndiaTimes - Published | DCGI seeks more data from SII over its application seeking emergency authorisation for CovovaxIndiaTimes - Published |
Serum Institute CEO hails WHO's approval of Covovax for emergency useIndiaTimes - Published | WHO approves SII's Covovax for emergency useCovavax is the Indian version of the Novavax vaccine brought in India by the Serum Institute of India for children.DNA - Published |
Serum plans to launch Novavax shot for children in six monthsIndiaTimes - Published | Novavax COVID jab manufacturer reveals £400m Teesside plant expansion The company slated to manufacture tens of millions of Novavax coronavirus vaccines at its plant on Teesside has announced a £400m expansion plan for the site.Sky News - Published |
New variant may force drug companies to tweak Covid vaccination plansThe emergence of the Omicron strain could lead drug companies scrambling to the drawing board to tweak their Covid-19 vaccine plans. US firm Novavax and Russia’s Gamaleya Institute said on Monday..IndiaTimes - Published | Govt panel seeks additional data from SII, says Covovax not yet been approved in country of originIndiaTimes - Published |
Novavax files for emergency use listing of Covid-19 vaccine with WHOIndiaTimes - Published | Novavax Covid-19 vaccine receives first emergency use authorizationNovavax Inc and partner Serum Institute of India said on Monday they received emergency use authorization for their Covid-19 vaccine in Indonesia, making it the first approval anywhere in the world for..IndiaTimes - Published |
SII now aims to include kids aged 2 to 6 in vaccination trials in a monthThe Serum Institute of India has expanded Covovax’s paediatric trial in seven to 11 years age bracket across 10 sites in India, including Pune, after ensuring vaccine safety in adolescents. The..IndiaTimes - Published | Recruitment of volunteers for trial of Covid vaccine Covovax on children beginsIndiaTimes - Published |
Hopeful of launching Covovax for adults in October this year, for children in Q1-2022: Serum CEO Adar PoonawallaIndiaTimes - Published | Govt panel recommends against allowing SII to conduct trial of Covovax on children aged 2-17 yrsAn expert panel of the country's central drug authority on Wednesday recommended against granting permission to the Serum Institute of India (SII) to conduct the phase 2/3 trial of Covid-19 vaccine..IndiaTimes - Published |
Serum Institute's COVID-19 vaccine 'Covovax' likely to launch by SeptemberThe new vaccine shall be launched under the brand name of Covovax, which SII is manufacturing in partnership with US pharmaceutical firm Novovax.DNA - Published | COVID-19: Serum Institute's Novavax vaccine shows 90% overall efficacyNovavax in collaboration with Indian drug manufacturer Serum Institute of India is manufacturing these vaccines for India and low-income countries.DNA - Published |
Covid-19: Novavax set for India launch with Serum Institute of India as manufacturing partnerThe uncertain path to authorisation in the US for Novavax despite passing the efficacy test with an impressive score of 90.4% might see India emerge as a major destination for the shots with the Serum..IndiaTimes - Published | Novavax COVID jab 100% effective in protecting against moderate and severe disease, trial suggestsNovavax has said its COVID-19 vaccine is 100% effective in protecting against "moderate and severe disease" following its phase three trial results.Sky News - Published |
Mix and match vaccine study extended to include Moderna and Novavax jabs A study assessing the benefits of mixing and matching coronavirus vaccines has been extended to include the Moderna and Novavax jabs.Sky News - Published | |
